Zak Mir mention6 May 2026 16:03
Never quite know if its a good thing to feature on Zak's show.
6th May Abingdon Health plc (ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, a German biopharmaceutical company developing invobenitug (procizumab, AK1967), a first-in-class antibody therapy for life-threatening cardiogenic and septic shock. This partnership was first announced via RNS on 12 June 2025, without giving details of the customer or project at that time for confidentiality reasons. As legal manufacturer and CDMO partner, Abingdon Health is developing DPP3 InvoSelect, a lateral flow-based companion diagnostic (CDx) designed to identify the patients most likely to benefit from this targeted therapy.
Comment: It may be said quite fairly that ABDX has hit the big time as far as its technology and its partners, something which although factored into the share price of late, should have plenty of upside to run. Above 10.5p we have been looking for 14p as soon as the end of this month.